bioRxiv preprint doi: https://doi.org/10.1101/2020.07.06.190348; this version posted September 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

Role of SARS-CoV-2 in altering the RNA binding protein and miRNA directed
post-transcriptional regulatory networks in humans
Rajneesh Srivastava1, Swapna Vidhur Daulatabad1, Mansi Srivastava1* and Sarath Chandra
Janga1,2,3*
Department of Biohealth Informatics, School of Informatics and Computing, Indiana University Purdue
University, 719 Indiana Ave Ste 319, Walker Plaza Building, Indianapolis, Indiana 46202
2Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, 5021 Health
Information and Translational Sciences (HITS), 410 West 10th Street, Indianapolis, Indiana, 46202
3Department of Medical and Molecular Genetics, Indiana University School of Medicine, Medical Research
and Library Building, 975 West Walnut Street, Indianapolis, Indiana, 46202
* Correspondence can be addressed to : Mansi Srivastava (Email: mansriva@iupui.edu); Sarath Chandra
Janga (Email: scjanga@iupui.edu)
1

Abstract: The outbreak of a novel coronavirus SARS-CoV-2 responsible for COVID-19 pandemic
has caused worldwide public health emergency. Due to the constantly evolving nature of the
coronaviruses, SARS-CoV-2 mediated alteration on post-transcriptional gene regulation across
human tissues remains elusive. In this study, we analyze publicly available genomic datasets to
systematically dissect the crosstalk and dysregulation of human post-transcriptional regulatory
networks governed by RNA binding proteins (RBPs) and micro-RNAs (miRs), due to SARS-CoV-2
infection. We uncovered that 13 out of 29 SARS-CoV-2 encoded proteins directly interact with 51
human RBPs of which majority of them were abundantly expressed in gonadal tissues and immune
cells. We further performed a functional analysis of differentially expressed genes in mock-treated
versus SARS-CoV-2 infected lung cells that revealed enrichment for immune response, cytokinemediated signaling, and metabolism associated genes. This study also characterized the alternative
splicing events in SARS-CoV-2 infected cells compared to control demonstrating that skipped exons
and mutually exclusive exons were the most abundant events that potentially contributed to
differential outcomes in response to viral infection. Motif enrichment analysis on the RNA genomic
sequence of SARS-CoV-2 clearly revealed the enrichment for RBPs such as SRSFs, PCBPs, ELAVs,
and HNRNPs suggesting the sponging of RBPs by SARS-CoV-2 genome. A similar analysis to study
the interactions of miRs with SARS-CoV-2 revealed functionally important miRs that were highly
expressed in immune cells, suggesting that these interactions may contribute to the progression of
the viral infection and modulate host immune response across other human tissues. Given the need
to understand the interactions of SARS-CoV-2 with key post-transcriptional regulators in the human
genome, this study provides a systematic computational analysis to dissect the role of dysregulated
post-transcriptional regulatory networks controlled by RBPs and miRs, across tissues types during
SARS-CoV-2 infection.
Keywords: SARS-CoV-2, COVID-19, post-transcriptional regulation, RBPs, miRs, RNA
1. Introduction
An outbreak of coronavirus disease (COVID-19) caused by the newly discovered severe acute
respiratory syndrome coronavirus (SARS-CoV-2), started in December 2019, in the city of Wuhan,
Hubei province, China. As of September 16, 2020, COVID-19 has expanded globally with more than
30 million confirmed cases with over 944,000 deaths worldwide, imposing an unprecedented threat
to public health (https://www.worldometers.info/coronavirus/). In the past two decades, coronavirus
outbreak has resulted in viral epidemics including severe acute respiratory syndrome (SARS-CoV)
in 2002 with fatality of 10% and middle east respiratory syndrome (MERS-CoV) in 2012 with fatality
of 36% [1-4]. Both SARS-CoV and MERS-CoV were zoonotic viruses originating in bat and camels
respectively [5, 6]. However, the recurring emergence of highly pathogenic SARS-CoV, MERS-CoV
and now SARS-CoV-2 have indicated the potential for cross-species transmission of these viruses
thus raising a serious public health concern [7, 8]. SARS CoV-2 shares a sequence similarity of 80%

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.06.190348; this version posted September 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

and 50% with previously identified SARS-CoV and MERS-CoV respectively [9-12]. Since its
emergence, rapid efforts have illustrated the molecular features of SARS-CoV-2 that enables it to
hijack the host cellular machinery and facilitates its genomic replication and assembly into new
virions during the infection process [13-16].
Coronavirus carries the largest genome among all RNA viruses, ranging from 26 to 32 kilobases
in length [12]. This virus has a characteristic â€œcrownâ€ like appearance under two-dimensional
transmission electron microscopy. SARS-CoV-2 is an enveloped positive-sense, single-stranded
ribonucleic acid (RNA) coronavirus that belongs to the genus beta-coronavirus. Upon entry in the
cell, SARS-CoV-2 RNA is translated into non-structural proteins (nsps) from two open reading frames
(ORFs), ORF1a, and ORF1b [17, 18]. The ORF1a produces polypeptide 1a that is cleaved further into
11 nsps, while ORF1b, yields polypeptide 1ab, that is cleaved into 16 nsps [17, 18]. Since SARS-CoV2 utilizes human machinery to translate its RNA after the entry into the cell, it could possibly impact
several RNA-binding proteins from the host to bind the viral genome resulting in altered posttranscriptional regulation. Next, the viral genome is used as the template for replication and
transcription, mediated by non-structural protein, RNA-dependent RNA polymerase (RdRP) [18, 19].
SARS-CoV-2 encodes four main structural proteins: spike (S), envelope (E), membrane (M), and
nucleocapsid (N) that are conserved and several other accessory proteins (3a, 6, 7a, 7b, 8, and 10)
according to the current annotation (GenBank: NC_045512.2) [17, 20]. The spike protein, that has
evolved the most during the COVID-19 outbreak, enables the virus to bind to angiotensin-converting
enzyme 2 (ACE2) on the host cell membrane, following which it undergoes structural changes and
subsequently allows the viral genome to make its way inside the host cell [21]. Infections caused by
these viruses result in severe pneumonia, fever and breathing difficulty [22].
Protein-protein interaction map between SARS-CoV-2 and human proteins published recently
has revealed several important targets for drug repurposing [23]. Given the evolving nature of
coronaviruses that results in frequent genetic diversity in their genome, it is crucial to identify the
regulators in humans that interact with the viral genome and their cross talk that results in altered
regulatory mechanisms in the host during the infection process. Therefore, it is imperative to
investigate the interacting post-transcriptional regulators that asset these viral proteins in different
tissues.
RNA-binding proteins (RBPs) are a class of proteins in humans that bind to single or double
stranded RNA and facilitate the formation of ribonucleoprotein complexes [24-26]. In addition to
RBPs, micro-RNAs (miRs) that belong to a class of non-coding RNAs also interact with target RNAs
to regulate cognate RNA expression [27, 28]. Both RBPs and miRs have been widely recognized in
regulating the post-transcriptional gene regulatory network in humans [29-31]. Dysregulated RBPs
and miRs have been shown to contribute significantly to altered regulatory network in a plethora of
diseases such as cancer, genetic diseases and viral infections [32-38]. Previous studies have shown
that human RBPs including heterogeneous Nuclear Ribonucleoprotein family (hnRNPA1 and
hnRNPAQ), polypyrimidine tract-binding protein (PTB), Serine/Arginine-Rich Splicing Factor 7
(SRSF7) and Transformer 2 Alpha Homolog (TRA2A) interact with coronavirus RNA [39-44].
Likewise, other reports have demonstrated the potential interaction between human miRNA and
viral genome including variety of coronaviruses [41, 45, 46]. However, the potential RBPs and miRs
that interact with SARS-CoV-2 and their implication in viral pathogenesis has been poorly
understood.
Currently, there are no proven anti-viral therapeutics that are effective against the novel
coronavirus. Although, analysis of therapeutic targets for SARS-CoV-2 has been conducted to
identify potential drugs by computational methods [47], the targets have not clinically approved for
therapeutic applications. Alternative therapeutics like angiotensin receptor blockers have been
identified as tentative target candidates but have shown concerns associated with the loss of
angiotensin functions crucial for cell [48]. Therefore, to devise effective therapeutics, there is a need
to determine the cellular targets in humans that interact with the virus and result in altered functional
outcomes. In this study, we uncovered that several human RBPs and miRNAs harbor abundant
binding sites across the SARS-CoV-2 genome, illustrating the titration of post-transcriptional
regulators. Interestingly, we show that most of these regulators were predominantly expressed in

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.06.190348; this version posted September 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

gonadal tissues, adrenal, pancreas, and blood cells. Overall, this study will bridge the gap in our
understanding of the impact of SARS-CoV-2 infection on post-transcriptional regulatory networks.
2. Results and discussion
2.1. Protein-protein interaction network analysis for SARS-CoV-2 viral proteins reveals an extensive and
direct set of interactions for scores of functionally important human RBPs
We obtained the affinity purification-mass spectrometry (AP-MS) based SARS-CoV-2 and
human proteins interaction network established in HEK293 cells [23] and investigated the human
RBPs that directly interact with viral proteins. Our analysis revealed that SARS-CoV-2 encoded
proteins interact directly with 51 human RBPs (Fig. 1A). We observed that these primary interacting
RBPs were proven to serve several vital functions in the cells such as polyadenylate binding protein
4 (PABP-4) and Dead-box RNA helicases (DDX21 and DDX10), enzymes involved in translation
machinery such as eukaryotic translation initiation factor 4H (EIF4H) and ribosomal protein L36
(RPL36) (Fig. 1A). Among the direct interactors, the highly abundant cytoplasmic PABPs, known to
bind the 3â€™ polyA tail on eukaryotic mRNAs, has previously been reported to interact with polyA tail
in bovine coronavirus and mouse hepatitis virus [49-51]. Since SARS-CoV-2 is also composed of
polyadenylated RNA, it is likely that the host PABP could modulate the translation of coronavirus
genome through polyA binding. DDX10, another primary interactor observed in the analyzed
dataset, has been reported to interact with SARS-CoV-2 non-structural protein 8 (nsp8) [52]
suggesting that the identified host RBPs could be implicated in the regulatory processes of SARSCoV-2 genome synthesis. EIF4H, also found as one of the primary interactors, was reported to
interact with SARS-CoV-2 non-structural protein 9 (nsp9) in a recently published study [23].
Furthermore, among the immediate interactions, we also found human RBPs such as signal
recognition particle 19 (SRP19 and SRP54) and Golgin subfamily B member 1 (GOLGB1) that have
been well recognized for co-translational protein targeting to membrane and endoplasmic reticulum
to golgi vesicle-mediated transport [53, 54] (Fig. 1A). These results suggest that several human RBPs
that come in direct contact with SARS-CoV-2 proteins could contribute to virus assembly and export
and could therefore be implicated as therapeutic targets. However, such findings require in-depth
experimental validation in a tissue-specific context to support the functional involvement of the
identified RBPs in response to SARS-CoV-2 infection.

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.06.190348; this version posted September 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

Figure 1. Protein-protein interaction network analysis suggest an immediate interaction of human
RBPs with SARS-CoV-2 viral proteins (A) An integrated SARS-CoV-2 â€“ human RBP interaction
network. We obtained the MS-based SARS-CoV-2 viral protein to human protein interaction network
established in HEK293 cells and integrated with 1st neighbor interacting RBPs (obtained from
BioGRID). (B) Protein abundance of SARS-CoV-2 interacting RBPs across human tissues. Expression
data were obtained from human protein map and row normalized. SARS-CoV-2 proteins were color
coded and highlighted in the network.

Further, we observed that among the SARS-CoV-2 encoded proteins, majority of the direct
interactions occurred with a range of non-structural proteins (nsp 2,5,8,9,11,13) that contribute to viral
replication and transcription along with structural proteins (E,N and M) (Fig. 1A). Therefore, it is
likely that the identified human RBPs that interact with viral proteins assist in the viral pathogenesis.
Furthermore, we also observed that ~65% of annotated human RBPs [55] were in immediate
neighborhood (obtained from BioGRID [56], shown at the center in Fig. 1A) of virus-protein
interacting RBPs and could indirectly regulate the SARS-CoV-2 proteins. Overall, the comprehensive
direct and indirect interactions between human RBPs and SARS-CoV-2 proteins is likely to rewire
the post-transcriptional gene regulatory mechanisms in human cells.
Next, we examined the abundance of SARS-CoV-2 interacting RBPs across human tissues using
the protein expression data from human proteome map [57]. Our results suggest that majority of the
human RBPs that have direct interaction with SARS-CoV-2 proteins were predominantly expressed
in gonadal tissues (Testis and Ovary) (Fig. 1B). These findings agreed with a recent study showing
that male reproductive systems are vulnerable to SARS-CoV-2 infection, that was evident by dramatic
changes in sex hormones of the infected patients suggesting gonadal function impairment [58, 59].
Additionally, we also found that, these SARS-CoV-2 interacting human RBPs were showing
relatively higher expression in immune cell types such as T cells (CD4+ and CD8+) and NK cells that
are a part of innate anti-viral immune response (Fig. 1B). Our observations are supported by recently
published studies suggesting that T cells, CD4+ T cells, and CD8+ T cells play a significant antiviral
role during SARS-CoV-2 infection [20, 60-63]. Overall, the results from this analysis provide a
systematic dissection of potential RBPs in humans interacting with SARS-CoV-2 proteins across
tissues.
2.2. SARS-CoV-2 infected lung epithelial cells exhibit gene expression alterations in several immunological
and metabolic pathways.
Due to rapidly evolving nature of SARS-CoV-2, the transcriptomic alterations contributed by the
virus in human remains unclear. To gain insight into the effect of SARS-CoV-2 infection on host gene
expression, we obtained the raw RNA sequencing data in normal versus SARS-CoV-2 infected
human bronchial epithelial (NHBE) cells [64] deposited in Gene Expression Omnibus (GEO) [65]. We
investigated the gene expression levels between the mock treated versus SARS-CoV-2 infected NHBE
cells and identified 327 differentially expressed genes at 5% FDR (among which ~67% shows >1.25
fold elevated expression in SARS-CoV-2 infected NHBE cells as shown in Fig. S1). We conducted
functional pathways associated with these differentially expressed genes (Fig. 2A, Fig. S1) and
identified 327 differentially expressed genes (at 5% FDR) using ClueGO [66] revealed an enrichment
for immune response, cytokine mediated signaling, inflammatory response and metabolism
associated genes (Fig. 2A, Table S1).

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.06.190348; this version posted September 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

Figure 2. Differential expression analysis of mock treated versus SARS-CoV-2 infected primary
human lung epithelial cells. (A) Bar-plot illustrating the significant pathways obtained from GOterm based functional grouping of differentially expressed genes (DEGs) at 5% fdr using ClueGO
analysis (Cytoscape plugin) (B) Row normalized expression profile of differentially expressed RBPs
in mock treated and SARS-CoV-2 infected primary human lung epithelial cells (in biological
triplicates).

We observed a significant enrichment for the IL-17 pathway associated genes during SARS-CoV2 infection (Fig. 2A). Our observation of overrepresented IL-17 pathway was in accordance with
recent studies that show overactivation of IL-17 producing Th17 cells during severe immune injury
in SARS-CoV-2 patients [67-69]. In addition to this, a recent review has summarized that targeting
IL-17 is immunologically plausible as a therapeutic strategy to prevent acute respiratory distress
syndrome (ARDS) during SARS-CoV-2 infection, based on previous evidence that mice lacking
functional IL-17 receptor (Il17raâˆ’/âˆ’) signaling were shown to be more susceptible than wild-type mice
to secondary pneumonia following infection with influenza A [70, 71]. Thus, our analysis
demonstrates the key role of several pathways including IL-17 cytokine response in SARS-CoV-2
infected cells.
Additional analysis also provided parallel support for the dysregulation of multiple RNA
binding proteins (FLNB, HDGF, ASS1, ZC3H12A, HK2, BST2, PPARGC1A) involved in immune
response, cytokine mediated signaling, and metabolism, when RNA-sequencing data from mock
treated versus SARS-CoV-2 infected lung cells was employed (Fig. 2B). Dysregulated expression of
multiple RBPs implicated in vital cellular functions suggests that the virus may hijack the host cellular

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.06.190348; this version posted September 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

machinery by modulating the expression of key RBPs. We also observed that six of these differentially
expressed genes that encode for RBPs were involved in at least 30% of the overrepresented pathways.
Overall, our results imply that differentially expressed RNA-binding proteins in SARS-CoV-2
infected cells may contribute to alterations in the post-transcriptional regulatory networks governed
by them.
2.3. Alternative splicing analysis revealed an abundance of skipped and mutually exclusive exons in human
transcripts during SARS-CoV-2 infection in lung epithelial cells.
Alternative splicing is a principal mechanism that contributes to protein diversity in eukaryotes,
while regulating physiologically important immune responses during bacterial and viral infections
[72]. Viral infections have been shown to cause global changes in the alternative splicing signatures
in the infected cells that may arise due to intrinsic factors like polymorphism at the splice sites or due
to direct intervention by virulence factors [73-75]. A previous study on virus-host interactions has
demonstrated that human coronavirus targets various signaling pathways of ER stress resulting in
differential splicing outcomes [76]. Another study has shown that deletion of E protein in
recombinant SARS-CoV resulted in significant XBP1 gene splicing and higher rate of apoptosis,
suggesting that coronavirus infected cells are susceptible to differential splicing events [77].
Therefore, we next investigated the alternative splicing events in mock vs SARS-CoV-2 treated NHBE
cells using rMATS (replicate Multivariate Analysis of Transcript Splicing) [78] (see Materials and
Methods).
Our analysis revealed an abundance for skipped and mutually exclusive exonic events in the
genes exhibiting alternative splicing events during SARS-CoV-2 infection at 5% fdr (Fig. 3A, Table
S2). We also observed that 81 of the alternatively spliced genes encoded for RBPs (indicated in blue,
Fig. 3A) and hence could result in altering the downstream post-transcriptional regulatory networks
in SARS-CoV-2 infected cells (Fig. 3A).

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.06.190348; this version posted September 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

Figure 3. Alternative splicing events during SARS-CoV-2 infection. (A) Bar plot showing the genes
(RBP encoding genes in blue) exhibiting alternative splicing during SARS-CoV-2 infection in primary
human lung epithelial cells (at 5% fdr). (B) Clustered GO-term network obtained from function
annotation analysis and grouping of the GO-term for the genes exhibiting alternative splicing using
ClueGO (cytoscape plugin). Significant clustering (adj. p < 1e-05) of functional groups were color
coded by functional annotation of the enriched GO-biological processes, with size of the nodes
indicating the level of significant association of genes per GO-term, were shown.

These findings enhance our mechanistic understanding of the SARS-CoV-2 induced alternative
splicing dysregulation in human cells and could be critical for developing novel therapeutic
strategies. Next, we identified the functional annotation of the enriched GO-terms related to the genes
exhibiting alternative splicing using ClueGO [66]. Our data revealed that majority of these genes were
enriched for vital biological processes including cellular protein localization, protein metabolism,
organelle organization, cellular biosynthetic process, cellular component assembly and cytochrome
c-mediated apoptotic response (Fig. 3B, Table S3). These findings suggest that processes that
contribute to cell structure, interaction, and growth upon SARS-CoV-2 infection via alternatively
spliced genes could contribute to rewiring of post-transcriptional network. In summary, this analysis
provides a clustered network of enriched biological functions that could be significantly dysregulated
in SARS-CoV-2 infected cells.
2.4. Motif enrichment analysis reveals potential human RBPs titrated by SARS-CoV-2 viral genome.
SARS-CoV-2 genome is the largest among the coronavirus family (~30kb) and has been
attributed to enhanced virus pathogenicity in the newly evolved strains of COVID-19 pandemic [18,
79]. Among the host derived cellular factors, RBPs have been recognized as active participants in all

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.06.190348; this version posted September 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

steps of viral infection [34, 80, 81]. A recent review has shown linkage of 472 human proteins with
viruses through unconventional RNA binding domains [81]. However, the role of RNA binding
proteins during viral pathogenesis has remained an unappreciated domain in viral research.
Therefore, in the present research, we conducted a systematic and comprehensive bioinformatic
study to investigate the RBPs that could potentially bind on RNA genome of SARS-CoV-2 by motif
enrichment analysis of human RBPs using FIMO [82] (see Materials and Methods). Motif analysis for
RBPs with established position specific weight matrices (PWMs) revealed significant number of
binding sites spread across the SARS-CoV-2 genome illustrating the possible titration of posttranscriptional regulators by viral genome (Fig. 4A, Fig. S2, Table S4). To date, the PWMs are available
only for a small fraction of the experimentally known human RBPs [83]. Thus, our analysis represents
an understanding of post-transcriptional interactions for ~7.5% of total RBPs collected from multiple
studies [24, 55, 84]. Importantly, the binding pattern of the RBP motifs across the entire normalized
length of the virus suggests that, several of human RBPs could be titrated across the viral genome
(Fig. 4A, Table S4). Our results showed an enrichment for RBPs such as SRSFs, PCBPs, ELAVs and
HNRNPs being most likely to get sponged on the viral genome (Fig. 4B). Our observation that specific
RBPs such as SRSF7, HNRNPA1 and TRA2A with well-known role in splicing exhibited binding sites
on SARS-CoV-2 RNA, is in agreement with a recently published study [85]. We found that most of
these RBPs were abundantly expressed in gonadal tissues, adrenal tissues, pancreas, and immune
cells including B cells, CD4+ T cells and NK cells (Fig. 4B). Our analysis revealed that several members
of SRSF family (SRSF 1,2,3,7,10) were potentially sponged by SARS-CoV-2 genome. Although SRSF2
has been reported to be predominantly nuclear, there is evidence for other SRSFs to be present in the
cytoplasmic compartment by nuclear to cytoplasmic shuttling [86-91]. Therefore, such cytoplasmic
binding and sequestration of SRSFs by SARS-CoV-2 RNA could contribute to dysregulation of host
RNA targets. Furthermore, previous reports indicate that plus-stranded RNA viruses, such as
polioviruses, utilize cellular factor PCBP for its translation and replication [44]. Therefore, we
speculate that SARS-CoV-2 could also utilize host cell RBPs such as PCBPs to facilitate its genomic
replication and translation. In addition to splicing factors and poly (rC) binding proteins, other
cellular RBPs such as ELAV1 that regulates stability of host transcripts could also stabilize viral RNAs
by sequestration on the viral genome [81, 92]. In summary, these findings suggest that SARS-CoV-2
could sponge human RBPs on its RNA resulting in altered post-transcriptional gene regulatory
network in the host cells. Targeting host proteins has been appreciated as an effective strategy to
combat a wide range of viral infections and therefore an understanding of the potential RBPs that are
likely sponged by the viral genome is crucial to develop novel therapeutics [35].

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.06.190348; this version posted September 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

Figure 4. Motif enrichment analysis reveals potential human RBPs titrated by SARS-CoV-2 viral
genome. (A) Violin plot shows the statistically significant (p-value < e-05) preferential binding profile
of RBP motifs (sorted by frequency of binding and greater than 10 sites) across the SARS-CoV-2 viral
genome (length normalized) identified using FIMO. (B) Hierarchically clustered heatmap showing
the protein abundance (row normalized) of RBPs across tissues.

2.5. SARS-CoV-2 genome titrates the abundance of functionally important miRs in human tissue
Micro RNAs (miRs) are small non-coding RNA molecules that function as central regulators of
post-transcriptional gene regulation. Human miRs have been associated with a variety of
pathophysiological pathways and demonstrate differential expression during viral infections [93, 94].
Recently, a few computational studies have shed light on the interplay between human miRs and
SARS-CoV-2 target genes indicating a crucial role in regulating the viral load in host cells [95, 96].
However, a comprehensive understanding of the functional role of host miRs during SARS-CoV-2
infection has remained elusive until now. Recently, a machine learning based study predicted that
miRs could impact SARS-CoV-2 infection through several mechanisms such as interfering with
replication, translation and by modulation of the host gene expression [95]. In this study, we used
computational approach to investigate the potential binding sites of human miRs in SARS-CoV-2
genome using FIMO [82]. We identified 22 miRNAs that could potentially bind throughout the length
of the SARS-CoV-2 viral genome (Fig. 5A, Table S5). Among the human miRs likely to be sequestered
on SARS-CoV-2 genome, miR-374a-3p has recently been predicted to target SARS-CoV-2 gene, in
particular it has been shown to target gene encoding the spike protein which is essential for virus
entry into the host cell [95, 97]. In addition to targeting the spike protein encoding genes, miR-374a3p is also predicted to target the ORF1ab in the SARS-CoV-2 genome that encodes for 5â€™viral replicase,
based on the function similarity of SARS-CoV-2 coding genes with SARS-CoV [98]. Our data
suggests that miRs can be bound by SARS-CoV-2 RNA, supporting a likely model where host miRs
can be sponged by SARS-CoV-2 and thereby contributing to decreased binding of miRs to the human
mRNA targets resulting in altering the expression patterns of human genes. Although less likely, it
is also possible that that nuclear pre-processed miRNAs complimentary to SARS-CoV-2 RNA could
be sequestered by viral RNA and because of this binding, miRNAs may not be able to do posttranscriptional gene silencing, thereby increasing the target gene expression. In either case, these
results suggest that several important miRs are likely being titrated by SARS-CoV-2 genome that
could result in dysregulation of post-transcriptional networks in the infected cells and could be

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.06.190348; this version posted September 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

attributed to viral pathogenesis. However, these results require experimental validation to conclude
their role in SARS-CoV-2 infection.

Figure 5. SARS-CoV-2 genome titrates the abundance of functionally important miRs in human tissue
(A) Violin plot shows the statistically significant (p-value < e-05) preferential binding profile of miRmotifs (sorted by frequency of binding >15 sites) across the SARS-CoV-2 viral genome (length
normalized) identified using FIMO. (B) Hierarchically clustered heatmap showing the log10
expression (CPM, row normalized) of miRs across tissues. (C) Bar-plot illustrating the significant
biological processes, obtained from gene ontology enrichment based functional grouping of miR
target genes (obtained from miRNet). Significant clustering (adj. p < 1e-10) of genes enriched in GObiological processes generated by ClueGO analysis (Cytoscape plugin).

Majority of the identified miRs were highly expressed in immune cells including CD8+T cells,
CD4+T, NK cells, CD14 cells and mast cells, suggesting that these miRs might contribute to altered
post-transcriptional regulation in specialized immune cells and assist in the progression of viral
infection and host immune response across other human tissues (Fig. 5B). Our results also indicate
that the high confident genes targeted by these sponged miRs were enriched for functional themes
including â€˜regulation of metabolic processesâ€™, â€˜post transcriptional gene regulationâ€™ and â€˜cell to cell
communicationâ€™ suggestive of a large-scale dysregulation across tissues (Fig. 5C, Table S6). Overall,
our results present a comprehensive analysis of the miRs being potentially titrated on the viral
genome resulting in altered post-transcriptional gene regulation. These findings provide enhances
our understanding of miR associated mechanism in SARS-CoV-2 pathogenesis and could provide
important clues for designing RNA based therapeutics.
3. Conclusion
Our analysis integrates a comprehensive interaction network to map the immediate interactions
between SARS-CoV-2 genome and proteome with human post-transcriptional regulators such as
RBPs and miRNAs along with their tissue specific expression and functional annotations. Given the
importance of developing effective therapeutic strategies in the current pandemic, understanding the
effect of SARS-CoV-2 infection on human transcriptional and post-transcriptional regulatory

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.06.190348; this version posted September 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

networks is crucial for identifying effective drug targets. To delineate the impact of SARS-CoV-2 on
host cells post-transcriptional gene regulatory network, we integrated the interactions between
SARS-CoV-2 encoded proteins with human RNA binding proteins. Our findings indicate 51 human
RBPs (including PABP-4, DDX21, DDX10, EIF4H) that interact directly with the viral structural and
non-structural proteins, that in turn interact indirectly with ~65% other secondary neighbor RBPs.
Thus, these findings suggest a comprehensive network of human RBPs and SARS-CoV-2 proteins
that could alter the post-transcriptional regulatory mechanisms at several layers in the infected cells.
We show that the expression profiles of majority of the directly interacting RBPs were associated
with gonadal tissues and immune cell types. Our study also highlights that several of the
differentially expressed genes in SARS-CoV-2 infected cells were enriched for biological pathways
such as immune response, cytokine mediated signaling, inflammatory response and metabolism
associated genes that are indispensable for cell survival. Importantly, we found that among the
differentially expressed genes, six RBP encoding genes contribute to functionally important
pathways in the host cells, implying a potential impact of SARS-CoV-2 infection on posttranscriptional regulation. Further, our analysis demonstrates the abundance of skipped exonic and
mutually exclusive exonic events in the SARS-CoV-2 infected cells, suggesting these alternative
splicing events as a plausible cause for altered post-transcriptional regulation in human cells. Using
motif enrichment analysis, we show that two key classes of post-transcriptional regulators, RBPs and
miRs are likely to be titrated by SARS-CoV-2 genome that could result in systemic dysregulation of
post-transcriptional networks in the infected cells. Currently, there are no effective anti-viral
therapies available for COVID-19. Therefore, our analyses provide a roadmap to enhance the
understanding of potential interactions of SARS-CoV-2 with key post-transcriptional regulators in
the human genome.
4. Materials and methods
4.1. Dissection of SARS-CoV-2 proteins interacting with human RBPs
We obtained the high confidence mass spectrometry based SARS-CoV-2 viral protein to human
protein interaction network established by Gordan et al, 2020 [23] in HEK293 cells. We dissected the
human RBPs directly interacting with viral proteins and integrated with 1st neighbor interacting RBPs
(obtained from BioGRID [56]). We also extracted the protein abundance of these SARS-CoV-2
interacting RBPs across human tissues from Human Proteome Map [57]. The abundance of these
proteins were hierarchically clustered and row normalized and represented as heatmap generated
from Morpheus (https://software.broadinstitute.org/morpheus/).
4.2. Differential expression analysis of mock treated versus SARS-CoV-2 infected primary human lung
epithelial cells.
We downloaded the raw RNA sequencing data deposited in Gene Expression Omnibus
(GEO)[65]. Specifically, we downloaded the paired end raw sequencing (FASTQ) files of mock
treated and SARS-CoV-2 (USA-WA1/2020) infected primary human lung epithelial cells (in biological
triplicates) using the Sequence Read Archive (SRA) Toolkit (fastq-dump command), from the GEO
cohort GSE147507 [64]. The quality of the sequence reads were ensured using FASTX-Toolkit
(http://hannonlab.cshl.edu/fastx_toolkit/) with a minimum of Phred quality score 20 for each sample.
We processed the raw sequencing reads using the in-house NGS data processing pipeline as
described previously[99, 100]. Briefly, we used Hierarchical Indexing for Spliced Alignment of
Transcripts (HISAT) [101] for aligning the short reads from RNA-seq experiments onto human
reference genome (hg38). SAM (Sequence Alignment/Map) files obtained from HISAT were postprocessed using SAMtools (version 0.1.19) [102, 103] for converting SAM to BAM (Binary
Alignment/Map) followed by sorting and indexing the output BAMs. The sorted BAM files were
parsed using the python script provided by StringTie (version 1.2.1) [104] to obtain the count matrix
of for gene levels across the samples. This count matrix was used to perform differential expression
analysis between mock vs SARS-CoV-2 infected NHBE cells using DE-seq2 [105]. Statistically

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.06.190348; this version posted September 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

significant (at 5% fdr) differentially expressed genes were collected for downstream data analysis.
Functional enrichment analysis of these genes was performed with p-value threshold < 10-10 using
ClueGO [66] (a Cytoscape [106] plugin) andrepresented as bar-plot illustrating the significant
pathways obtained from GO-term based functional grouping of differentially expressed genes.
4.3. Identification of alternative splicing events during SARS-CoV-2 infection.
We used rMATS (replicate Multivariate Analysis of Transcript Splicing) [78] to identify
differential alternative splicing (AS) events between the mock vs SARS-CoV-2 treated NHBE cells.
rMATS used sorted BAM (Binary Alignment/Map) files, obtained from aligning the fastq files against
hg38 reference genome using HISAT (as discussed above). It also uses a GTF file (gene transfer file
format), downloaded from Ensembl (version 97) [107] for existing annotation of exons. Briefly,
rMATS enabled the analysis of the inclusion/exclusion of target exons/introns contributing to
different types of alternative splicing events, namely skipped exon (SE), alternative 5â€™ splice site
(A5SS), alternative 3â€™ splice site (A3SS), mutually exclusive exons (MXE) and retained intron (RI),
between pair of conditions and provides the difference in level of inclusion of an exon denoted by
Percentage Splicing Index (ðœ“ðœ“ ð‘ ð‘ ð‘ ð‘ ð‘ ð‘ ð‘ ð‘ ð‘ ð‘ ) (as described previously [99]). Genes exhibiting alternatively
spliced events detected below 5% FDR threshold were documented in Table S2. Functional
enrichment analysis of these genes was performed using ClueGO [66] and documented in Table S3.
4.4. Identification of potential binding blocks of RBPs in SARS-CoV-2 viral genome using motif enrichment
analysis.
We obtained the RBP-motifs from ATtRACT [83] and scanned across the SARS-CoV-2 viral
genome using FIMO [82, 108] with default parameters. Resulting genomic locations for each RBP
motif were documented in Table S4. For each binding motif, the scanned genomic location was
normalized by considering the mid-point of genomic coordinate divided with the SARS-CoV-2
genome length. Also, the occurrence of each RBP motif binding across the viral genome was
computed. Statistically significant (p-value < 1e-05) preferential binding profile of RBP motifs (sorted
by frequency of binding and greater than 10 sites) across the SARS-CoV-2 viral genome (length
normalized) identified using FIMO [82] was visualized in violin plot. Also, the protein abundance of
corresponding RBPs were extracted from human proteome map[57] and represented as hierarchically
clustered heatmap across the tissues.
4.5. Identification of potential binding blocks of microRNAs in SARS-CoV-2 viral genome using motif
enrichment analysis.
We obtained the miR-motifs from MEME [108] and scanned across the SARS-CoV-2 viral
genome using FIMO[82, 108] with default parameters. Resulting genomic locations for each miRmotif were documented in Table S6. For each miR motif, the scanned genomic location was
normalized by considering the mid-point of genomic coordinate divided with the SARS-CoV-2
genome length. Also, the occurrence of each miR-motif binding across the viral genome was
computed. Statistically significant (p-value < 1e-05) preferential binding profile of miR-motifs (sorted
by frequency of binding and greater than 15 sites) across the SARS-CoV-2 viral genome (length
normalized) identified using FIMO was visualized in violin plot. Also, the expression profile of
corresponding miRs were extracted from FANTOM5 project[109] and represented as hierarchically
clustered heatmap across the tissues. To understand the generic biological function of these miRs,
that could be altered by being titrated by SARS-CoV-2 genome in host cells, we downloaded the high
confidence miR target genes (obtained from miRNet [110, 111]) and performed function annotation
analysis. Resulting significant biological processes, obtained from gene ontology enrichment based
functional grouping of these miR target genes were illustrated in barplot. Significant clustering (adj.
p < 1e-10) of genes enriched in GO-biological processes were generated by ClueGO [66] analysis (a
cytoscape [106] plugin).

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.06.190348; this version posted September 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

Acknowledgments: This work was supported by the National Institute of General Medical Sciences of the
National Institutes of Health under Award Number R01GM123314 (SCJ), and COVID19 Rapid Response grant
from IUPUI's Office of the Vice Chancellor for Research to SCJ. We also thank the lab members for their valuable
suggestions and supporting dataset required for completion of this project.
Authorsâ€™ contribution: RS, MS and SCJ conceived and designed the study. RS processed the publicly available
dataset and implemented the bioinformatic tools. RS and SVD integrated the supplementary dataset required
for downstream data analysis. RS, MS and SCJ interpreted the data and wrote the manuscript. All authors read
and approved the final manuscript.
Conflicts of interest: The authors report no financial or other conflict of interest relevant to the subject of this
article.

References
1.

de Wit, E.; van Doremalen, N.; Falzarano, D.; Munster, V. J., SARS and MERS: recent insights
into emerging coronaviruses. Nat Rev Microbiol 2016, 14, (8), 523-34.

2.

Meo, S. A.; Alhowikan, A. M.; Al-Khlaiwi, T.; Meo, I. M.; Halepoto, D. M.; Iqbal, M.; Usmani,
A. M.; Hajjar, W.; Ahmed, N., Novel coronavirus 2019-nCoV: prevalence, biological and
clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur Rev Med Pharmacol
Sci 2020, 24, (4), 2012-2019.

3.

Zaki, A. M.; van Boheemen, S.; Bestebroer, T. M.; Osterhaus, A. D.; Fouchier, R. A., Isolation
of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012, 367,
(19), 1814-20.

4.

Cheng, V. C.; Lau, S. K.; Woo, P. C.; Yuen, K. Y., Severe acute respiratory syndrome
coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev 2007, 20,
(4), 660-94.

5.

Hajjar, S. A.; Memish, Z. A.; McIntosh, K., Middle East Respiratory Syndrome Coronavirus
(MERS-CoV): a perpetual challenge. Ann Saudi Med 2013, 33, (5), 427-36.

6.

Bolles, M.; Donaldson, E.; Baric, R., SARS-CoV and emergent coronaviruses: viral
determinants of interspecies transmission. Curr Opin Virol 2011, 1, (6), 624-34.

7.

Su, S.; Wong, G.; Shi, W.; Liu, J.; Lai, A. C. K.; Zhou, J.; Liu, W.; Bi, Y.; Gao, G. F.,
Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. Trends Microbiol
2016, 24, (6), 490-502.

8.

Menachery, V. D.; Graham, R. L.; Baric, R. S., Jumping species-a mechanism for coronavirus
persistence and survival. Curr Opin Virol 2017, 23, 1-7.

9.

Zheng, J., SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat. Int J Biol Sci
2020, 16, (10), 1678-1685.

10.

Xu, J.; Zhao, S.; Teng, T.; Abdalla, A. E.; Zhu, W.; Xie, L.; Wang, Y.; Guo, X., Systematic
Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2
and SARS-CoV. Viruses 2020, 12, (2).

11.

Gralinski, L. E.; Menachery, V. D., Return of the Coronavirus: 2019-nCoV. Viruses 2020, 12,
(2).

12.

Wang, H.; Li, X.; Li, T.; Zhang, S.; Wang, L.; Wu, X.; Liu, J., The genetic sequence, origin, and
diagnosis of SARS-CoV-2. Eur J Clin Microbiol Infect Dis 2020, 39, (9), 1629-1635.

13.

He, J.; Tao, H.; Yan, Y.; Huang, S. Y.; Xiao, Y., Molecular Mechanism of Evolution and Human
Infection with SARS-CoV-2. Viruses 2020, 12, (4).

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.06.190348; this version posted September 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

14.

Trubsbach, A.; Dokert, B.; Schentke, K. U.; Jaross, W., [Lipid analysis of bile for determination
of lithogeneity of bile and reproducibility of results with duodenal B bile]. Z Med Lab Diagn
1982, 23, (1), 30-4.

15.

Kang, S.; Peng, W.; Zhu, Y.; Lu, S.; Zhou, M.; Lin, W.; Wu, W.; Huang, S.; Jiang, L.; Luo, X.;
Deng, M., Recent progress in understanding 2019 novel coronavirus (SARS-CoV-2)
associated with human respiratory disease: detection, mechanisms and treatment. Int J
Antimicrob Agents 2020, 55, (5), 105950.

16.

Malle, L., A map of SARS-CoV-2 and host cell interactions. Nat Rev Immunol 2020, 20, (6), 351.

17.

Kim, D.; Lee, J. Y.; Yang, J. S.; Kim, J. W.; Kim, V. N.; Chang, H., The Architecture of SARSCoV-2 Transcriptome. Cell 2020, 181, (4), 914-921 e10.

18.

Khailany, R. A.; Safdar, M.; Ozaslan, M., Genomic characterization of a novel SARS-CoV-2.
Gene Rep 2020, 19, 100682.

19.

Elfiky, A. A., SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico
perspective. J Biomol Struct Dyn 2020, 1-9.

20.

Astuti, I.; Ysrafil, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An
overview of viral structure and host response. Diabetes Metab Syndr 2020, 14, (4), 407-412.

21.

Guzzi, P. H.; Mercatelli, D.; Ceraolo, C.; Giorgi, F. M., Master Regulator Analysis of the SARSCoV-2/Human Interactome. J Clin Med 2020, 9, (4).

22.

Shereen, M. A.; Khan, S.; Kazmi, A.; Bashir, N.; Siddique, R., COVID-19 infection: Origin,
transmission, and characteristics of human coronaviruses. J Adv Res 2020, 24, 91-98.

23.

Gordon, D. E.; Jang, G. M.; Bouhaddou, M.; Xu, J.; Obernier, K.; White, K. M.; O'Meara, M. J.;
Rezelj, V. V.; Guo, J. Z.; Swaney, D. L.; Tummino, T. A.; Huttenhain, R.; Kaake, R. M.;
Richards, A. L.; Tutuncuoglu, B.; Foussard, H.; Batra, J.; Haas, K.; Modak, M.; Kim, M.; Haas,
P.; Polacco, B. J.; Braberg, H.; Fabius, J. M.; Eckhardt, M.; Soucheray, M.; Bennett, M. J.; Cakir,
M.; McGregor, M. J.; Li, Q.; Meyer, B.; Roesch, F.; Vallet, T.; Mac Kain, A.; Miorin, L.; Moreno,
E.; Naing, Z. Z. C.; Zhou, Y.; Peng, S.; Shi, Y.; Zhang, Z.; Shen, W.; Kirby, I. T.; Melnyk, J. E.;
Chorba, J. S.; Lou, K.; Dai, S. A.; Barrio-Hernandez, I.; Memon, D.; Hernandez-Armenta, C.;
Lyu, J.; Mathy, C. J. P.; Perica, T.; Pilla, K. B.; Ganesan, S. J.; Saltzberg, D. J.; Rakesh, R.; Liu,
X.; Rosenthal, S. B.; Calviello, L.; Venkataramanan, S.; Liboy-Lugo, J.; Lin, Y.; Huang, X. P.;
Liu, Y.; Wankowicz, S. A.; Bohn, M.; Safari, M.; Ugur, F. S.; Koh, C.; Savar, N. S.; Tran, Q. D.;
Shengjuler, D.; Fletcher, S. J.; O'Neal, M. C.; Cai, Y.; Chang, J. C. J.; Broadhurst, D. J.;
Klippsten, S.; Sharp, P. P.; Wenzell, N. A.; Kuzuoglu-Ozturk, D.; Wang, H. Y.; Trenker, R.;
Young, J. M.; Cavero, D. A.; Hiatt, J.; Roth, T. L.; Rathore, U.; Subramanian, A.; Noack, J.;
Hubert, M.; Stroud, R. M.; Frankel, A. D.; Rosenberg, O. S.; Verba, K. A.; Agard, D. A.; Ott,
M.; Emerman, M.; Jura, N.; von Zastrow, M.; Verdin, E.; Ashworth, A.; Schwartz, O.; d'Enfert,
C.; Mukherjee, S.; Jacobson, M.; Malik, H. S.; Fujimori, D. G.; Ideker, T.; Craik, C. S.; Floor, S.
N.; Fraser, J. S.; Gross, J. D.; Sali, A.; Roth, B. L.; Ruggero, D.; Taunton, J.; Kortemme, T.;
Beltrao, P.; Vignuzzi, M.; Garcia-Sastre, A.; Shokat, K. M.; Shoichet, B. K.; Krogan, N. J., A
SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 2020, 583,
(7816), 459-468.

24.

Hentze, M. W.; Castello, A.; Schwarzl, T.; Preiss, T., A brave new world of RNA-binding
proteins. Nat Rev Mol Cell Biol 2018, 19, (5), 327-341.

25.

Dassi, E., Handshakes and Fights: The Regulatory Interplay of RNA-Binding Proteins. Front
Mol Biosci 2017, 4, 67.

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.06.190348; this version posted September 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

26.

Corley, M.; Burns, M. C.; Yeo, G. W., How RNA-Binding Proteins Interact with RNA:
Molecules and Mechanisms. Mol Cell 2020, 78, (1), 9-29.

27.

O'Brien, J.; Hayder, H.; Zayed, Y.; Peng, C., Overview of MicroRNA Biogenesis, Mechanisms
of Actions, and Circulation. Front Endocrinol (Lausanne) 2018, 9, 402.

28.

Hammond, S. M., An overview of microRNAs. Adv Drug Deliv Rev 2015, 87, 3-14.

29.

Glisovic, T.; Bachorik, J. L.; Yong, J.; Dreyfuss, G., RNA-binding proteins and posttranscriptional gene regulation. FEBS Lett 2008, 582, (14), 1977-86.

30.

Zanzoni, A.; Spinelli, L.; Ribeiro, D. M.; Tartaglia, G. G.; Brun, C., Post-transcriptional
regulatory patterns revealed by protein-RNA interactions. Sci Rep 2019, 9, (1), 4302.

31.

Chen, P. Y.; Meister, G., microRNA-guided posttranscriptional gene regulation. Biol Chem
2005, 386, (12), 1205-18.

32.

Brinegar, A. E.; Cooper, T. A., Roles for RNA-binding proteins in development and disease.
Brain Res 2016, 1647, 1-8.

33.

Lukong, K. E.; Chang, K. W.; Khandjian, E. W.; Richard, S., RNA-binding proteins in human
genetic disease. Trends Genet 2008, 24, (8), 416-25.

34.

Li, Z.; Nagy, P. D., Diverse roles of host RNA binding proteins in RNA virus replication. RNA
Biol 2011, 8, (2), 305-15.

35.

Garcia-Moreno, M.; Noerenberg, M.; Ni, S.; Jarvelin, A. I.; Gonzalez-Almela, E.; Lenz, C. E.;
Bach-Pages, M.; Cox, V.; Avolio, R.; Davis, T.; Hester, S.; Sohier, T. J. M.; Li, B.; Heikel, G.;
Michlewski, G.; Sanz, M. A.; Carrasco, L.; Ricci, E. P.; Pelechano, V.; Davis, I.; Fischer, B.;
Mohammed, S.; Castello, A., System-wide Profiling of RNA-Binding Proteins Uncovers Key
Regulators of Virus Infection. Mol Cell 2019, 74, (1), 196-211 e11.

36.

Ardekani, A. M.; Naeini, M. M., The Role of MicroRNAs in Human Diseases. Avicenna J Med
Biotechnol 2010, 2, (4), 161-79.

37.

Drury, R. E.; O'Connor, D.; Pollard, A. J., The Clinical Application of MicroRNAs in Infectious
Disease. Front Immunol 2017, 8, 1182.

38.

Girardi, E.; Lopez, P.; Pfeffer, S., On the Importance of Host MicroRNAs During Viral
Infection. Front Genet 2018, 9, 439.

39.

Srinivasan, S.; Cui, H.; Gao, Z.; Liu, M.; Lu, S.; Mkandawire, W.; Narykov, O.; Sun, M.;
Korkin, D., Structural Genomics of SARS-CoV-2 Indicates Evolutionary Conserved
Functional Regions of Viral Proteins. Viruses 2020, 12, (4).

40.

Maranon, D. G.; Anderson, J. R.; Maranon, A. G.; Wilusz, J., The interface between
coronaviruses and host cell RNA biology: Novel potential insights for future therapeutic
intervention. Wiley Interdiscip Rev RNA 2020, 11, (5), e1614.

41.

Mukherjee, M.; Goswami, S., Global cataloguing of variations in untranslated regions of viral
genome and prediction of key host RNA binding protein-microRNA interactions modulating
genome stability in SARS-CoV-2. PLoS One 2020, 15, (8), e0237559.

42.

Luo, H.; Chen, Q.; Chen, J.; Chen, K.; Shen, X.; Jiang, H., The nucleocapsid protein of SARS
coronavirus has a high binding affinity to the human cellular heterogeneous nuclear
ribonucleoprotein A1. FEBS Lett 2005, 579, (12), 2623-8.

43.

Sola, I.; Galan, C.; Mateos-Gomez, P. A.; Palacio, L.; Zuniga, S.; Cruz, J. L.; Almazan, F.;
Enjuanes, L., The polypyrimidine tract-binding protein affects coronavirus RNA
accumulation levels and relocalizes viral RNAs to novel cytoplasmic domains different from
replication-transcription sites. J Virol 2011, 85, (10), 5136-49.

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.06.190348; this version posted September 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

44.

Sola, I.; Mateos-Gomez, P. A.; Almazan, F.; Zuniga, S.; Enjuanes, L., RNA-RNA and RNAprotein interactions in coronavirus replication and transcription. RNA Biol 2011, 8, (2), 23748.

45.

Mallick, B.; Ghosh, Z.; Chakrabarti, J., MicroRNome analysis unravels the molecular basis of
SARS infection in bronchoalveolar stem cells. PLoS One 2009, 4, (11), e7837.

46.

Peng, X.; Gralinski, L.; Ferris, M. T.; Frieman, M. B.; Thomas, M. J.; Proll, S.; Korth, M. J.;
Tisoncik, J. R.; Heise, M.; Luo, S.; Schroth, G. P.; Tumpey, T. M.; Li, C.; Kawaoka, Y.; Baric, R.
S.; Katze, M. G., Integrative deep sequencing of the mouse lung transcriptome reveals
differential expression of diverse classes of small RNAs in response to respiratory virus
infection. mBio 2011, 2, (6).

47.

Wu, C.; Liu, Y.; Yang, Y.; Zhang, P.; Zhong, W.; Wang, Y.; Wang, Q.; Xu, Y.; Li, M.; Li, X.;
Zheng, M.; Chen, L.; Li, H., Analysis of therapeutic targets for SARS-CoV-2 and discovery of
potential drugs by computational methods. Acta Pharm Sin B 2020, 10, (5), 766-788.

48.

Gurwitz, D., Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev
Res 2020, 81, (5), 537-540.

49.

Shi, S. T.; Lai, M. M., Viral and cellular proteins involved in coronavirus replication. Curr Top
Microbiol Immunol 2005, 287, 95-131.

50.

Spagnolo, J. F.; Hogue, B. G., Host protein interactions with the 3' end of bovine coronavirus
RNA and the requirement of the poly(A) tail for coronavirus defective genome replication. J
Virol 2000, 74, (11), 5053-65.

51.

Yu, W.; Leibowitz, J. L., Specific binding of host cellular proteins to multiple sites within the
3' end of mouse hepatitis virus genomic RNA. J Virol 1995, 69, (4), 2016-23.

52.

Tutuncuoglu, B.; Cakir, M.; Batra, J.; Bouhaddou, M.; Eckhardt, M.; Gordon, D. E.; Krogan,
N. J., The Landscape of Human Cancer Proteins Targeted by SARS-CoV-2. Cancer Discov
2020, 10, (7), 916-921.

53.

Nyathi, Y.; Wilkinson, B. M.; Pool, M. R., Co-translational targeting and translocation of
proteins to the endoplasmic reticulum. Biochimica et biophysica acta 2013, 1833, (11), 2392-402.

54.

Saraogi, I.; Shan, S. O., Molecular mechanism of co-translational protein targeting by the
signal recognition particle. Traffic 2011, 12, (5), 535-42.

55.

Hashemikhabir, S.; Neelamraju, Y.; Janga, S. C., Database of RNA binding protein expression
and disease dynamics (READ DB). Database : the journal of biological databases and curation 2015,
2015, bav072.

56.

Chatr-Aryamontri, A.; Breitkreutz, B. J.; Oughtred, R.; Boucher, L.; Heinicke, S.; Chen, D.;
Stark, C.; Breitkreutz, A.; Kolas, N.; O'Donnell, L.; Reguly, T.; Nixon, J.; Ramage, L.; Winter,
A.; Sellam, A.; Chang, C.; Hirschman, J.; Theesfeld, C.; Rust, J.; Livstone, M. S.; Dolinski, K.;
Tyers, M., The BioGRID interaction database: 2015 update. Nucleic Acids Res 2015, 43,
(Database issue), D470-8.

57.

Kim, M. S.; Pinto, S. M.; Getnet, D.; Nirujogi, R. S.; Manda, S. S.; Chaerkady, R.; Madugundu,
A. K.; Kelkar, D. S.; Isserlin, R.; Jain, S.; Thomas, J. K.; Muthusamy, B.; Leal-Rojas, P.; Kumar,
P.; Sahasrabuddhe, N. A.; Balakrishnan, L.; Advani, J.; George, B.; Renuse, S.; Selvan, L. D.;
Patil, A. H.; Nanjappa, V.; Radhakrishnan, A.; Prasad, S.; Subbannayya, T.; Raju, R.; Kumar,
M.; Sreenivasamurthy, S. K.; Marimuthu, A.; Sathe, G. J.; Chavan, S.; Datta, K. K.;
Subbannayya, Y.; Sahu, A.; Yelamanchi, S. D.; Jayaram, S.; Rajagopalan, P.; Sharma, J.;
Murthy, K. R.; Syed, N.; Goel, R.; Khan, A. A.; Ahmad, S.; Dey, G.; Mudgal, K.; Chatterjee,

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.06.190348; this version posted September 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

A.; Huang, T. C.; Zhong, J.; Wu, X.; Shaw, P. G.; Freed, D.; Zahari, M. S.; Mukherjee, K. K.;
Shankar, S.; Mahadevan, A.; Lam, H.; Mitchell, C. J.; Shankar, S. K.; Satishchandra, P.;
Schroeder, J. T.; Sirdeshmukh, R.; Maitra, A.; Leach, S. D.; Drake, C. G.; Halushka, M. K.;
Prasad, T. S.; Hruban, R. H.; Kerr, C. L.; Bader, G. D.; Iacobuzio-Donahue, C. A.; Gowda, H.;
Pandey, A., A draft map of the human proteome. Nature 2014, 509, (7502), 575-81.
58.

Wang, S.; Zhou, X.; Zhang, T.; Wang, Z., The need for urogenital tract monitoring in COVID19. Nat Rev Urol 2020, 17, (6), 314-315.

59.

Ma, L.; Xie, W.; Li, D.; Shi, L.; Mao, Y.; Xiong, Y.; Zhang, Y.; Zhang, M., Effect of SARS-CoV2 infection upon male gonadal function: A single center-based study. medRxiv 2020.

60.

Li, G.; Fan, Y.; Lai, Y.; Han, T.; Li, Z.; Zhou, P.; Pan, P.; Wang, W.; Hu, D.; Liu, X.; Zhang, Q.;
Wu, J., Coronavirus infections and immune responses. J Med Virol 2020, 92, (4), 424-432.

61.

Wang, X.; Xu, W.; Hu, G.; Xia, S.; Sun, Z.; Liu, Z.; Xie, Y.; Zhang, R.; Jiang, S.; Lu, L.,
RETRACTED ARTICLE: SARS-CoV-2 infects T lymphocytes through its spike proteinmediated membrane fusion. Cell Mol Immunol 2020.

62.

Zheng, M.; Gao, Y.; Wang, G.; Song, G.; Liu, S.; Sun, D.; Xu, Y.; Tian, Z., Functional exhaustion
of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol 2020, 17, (5), 533-535.

63.

Braun, J.; Loyal, L.; Frentsch, M.; Wendisch, D.; Georg, P.; Kurth, F.; Hippenstiel, S.;
Dingeldey, M.; Kruse, B.; Fauchere, F.; Baysal, E.; Mangold, M.; Henze, L.; Lauster, R.; Mall,
M. A.; Beyer, K.; Rohmel, J.; Voigt, S.; Schmitz, J.; Miltenyi, S.; Demuth, I.; Muller, M. A.;
Hocke, A.; Witzenrath, M.; Suttorp, N.; Kern, F.; Reimer, U.; Wenschuh, H.; Drosten, C.;
Corman, V. M.; Giesecke-Thiel, C.; Sander, L. E.; Thiel, A., SARS-CoV-2-reactive T cells in
healthy donors and patients with COVID-19. Nature 2020.

64.

Blanco-Melo, D.; Nilsson-Payant, B. E.; Liu, W. C.; Uhl, S.; Hoagland, D.; Moller, R.; Jordan,
T. X.; Oishi, K.; Panis, M.; Sachs, D.; Wang, T. T.; Schwartz, R. E.; Lim, J. K.; Albrecht, R. A.;
tenOever, B. R., Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID19. Cell 2020, 181, (5), 1036-1045 e9.

65.

Barrett, T.; Wilhite, S. E.; Ledoux, P.; Evangelista, C.; Kim, I. F.; Tomashevsky, M.; Marshall,
K. A.; Phillippy, K. H.; Sherman, P. M.; Holko, M.; Yefanov, A.; Lee, H.; Zhang, N.; Robertson,
C. L.; Serova, N.; Davis, S.; Soboleva, A., NCBI GEO: archive for functional genomics data
sets--update. Nucleic Acids Res 2013, 41, (Database issue), D991-5.

66.

Bindea, G.; Mlecnik, B.; Hackl, H.; Charoentong, P.; Tosolini, M.; Kirilovsky, A.; Fridman, W.
H.; Pages, F.; Trajanoski, Z.; Galon, J., ClueGO: a Cytoscape plug-in to decipher functionally
grouped gene ontology and pathway annotation networks. Bioinformatics 2009, 25, (8), 10913.

67.

Xu, Z.; Shi, L.; Wang, Y.; Zhang, J.; Huang, L.; Zhang, C.; Liu, S.; Zhao, P.; Liu, H.; Zhu, L.;
Tai, Y.; Bai, C.; Gao, T.; Song, J.; Xia, P.; Dong, J.; Zhao, J.; Wang, F. S., Pathological findings
of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020, 8,
(4), 420-422.

68.

Zhang, C.; Wu, Z.; Li, J. W.; Zhao, H.; Wang, G. Q., Cytokine release syndrome in severe
COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.
Int J Antimicrob Agents 2020, 55, (5), 105954.

69.

Wu, D.; Yang, X. O., TH17 responses in cytokine storm of COVID-19: An emerging target of
JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect 2020, 53, (3), 368-370.

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.06.190348; this version posted September 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

70.

Kudva, A.; Scheller, E. V.; Robinson, K. M.; Crowe, C. R.; Choi, S. M.; Slight, S. R.; Khader, S.
A.; Dubin, P. J.; Enelow, R. I.; Kolls, J. K.; Alcorn, J. F., Influenza A inhibits Th17-mediated
host defense against bacterial pneumonia in mice. J Immunol 2011, 186, (3), 1666-1674.

71.

Pacha, O.; Sallman, M. A.; Evans, S. E., COVID-19: a case for inhibiting IL-17? Nat Rev
Immunol 2020, 20, (6), 345-346.

72.

Chauhan, K.; Kalam, H.; Dutt, R.; Kumar, D., RNA Splicing: A New Paradigm in HostPathogen Interactions. Journal of molecular biology 2019, 431, (8), 1565-1575.

73.

Ashraf, U.; Benoit-Pilven, C.; Lacroix, V.; Navratil, V.; Naffakh, N., Advances in Analyzing
Virus-Induced Alterations of Host Cell Splicing. Trends Microbiol 2019, 27, (3), 268-281.

74.

Boudreault, S.; Roy, P.; Lemay, G.; Bisaillon, M., Viral modulation of cellular RNA alternative
splicing: A new key player in virus-host interactions? Wiley Interdiscip Rev RNA 2019, 10, (5),
e1543.

75.

Bojkova, D.; Klann, K.; Koch, B.; Widera, M.; Krause, D.; Ciesek, S.; Cinatl, J.; MÃ¼nch, C.,
SARS-CoV-2 infected host cell proteomics reveal potential therapy targets. 2020.

76.

Lim, Y. X.; Ng, Y. L.; Tam, J. P.; Liu, D. X., Human Coronaviruses: A Review of Virus-Host
Interactions. Diseases 2016, 4, (3).

77.

DeDiego, M. L.; Nieto-Torres, J. L.; Jimenez-Guardeno, J. M.; Regla-Nava, J. A.; Alvarez, E.;
Oliveros, J. C.; Zhao, J.; Fett, C.; Perlman, S.; Enjuanes, L., Severe acute respiratory syndrome
coronavirus envelope protein regulates cell stress response and apoptosis. PLoS Pathog 2011,
7, (10), e1002315.

78.

Shen, S.; Park, J. W.; Lu, Z. X.; Lin, L.; Henry, M. D.; Wu, Y. N.; Zhou, Q.; Xing, Y., rMATS:
robust and flexible detection of differential alternative splicing from replicate RNA-Seq data.
Proceedings of the National Academy of Sciences of the United States of America 2014, 111, (51),
E5593-601.

79.

Forster, P.; Forster, L.; Renfrew, C.; Forster, M., Phylogenetic network analysis of SARS-CoV2 genomes. Proceedings of the National Academy of Sciences of the United States of America 2020,
117, (17), 9241-9243.

80.

Zhu, J.; Gopinath, K.; Murali, A.; Yi, G.; Hayward, S. D.; Zhu, H.; Kao, C., RNA-binding
proteins that inhibit RNA virus infection. Proceedings of the National Academy of Sciences of the
United States of America 2007, 104, (9), 3129-34.

81.

Garcia-Moreno, M.; Jarvelin, A. I.; Castello, A., Unconventional RNA-binding proteins step
into the virus-host battlefront. Wiley Interdiscip Rev RNA 2018, 9, (6), e1498.

82.

Grant, C. E.; Bailey, T. L.; Noble, W. S., FIMO: scanning for occurrences of a given motif.
Bioinformatics 2011, 27, (7), 1017-8.

83.

Giudice, G.; Sanchez-Cabo, F.; Torroja, C.; Lara-Pezzi, E., ATtRACT-a database of RNAbinding proteins and associated motifs. Database : the journal of biological databases and curation
2016, 2016.

84.

Castello, A.; Fischer, B.; Eichelbaum, K.; Horos, R.; Beckmann, B. M.; Strein, C.; Davey, N. E.;
Humphreys, D. T.; Preiss, T.; Steinmetz, L. M.; Krijgsveld, J.; Hentze, M. W., Insights into
RNA biology from an atlas of mammalian mRNA-binding proteins. Cell 2012, 149, (6), 1393406.

85.

Bartas, M.; Brazda, V.; Bohalova, N.; Cantara, A.; Volna, A.; Stachurova, T.; Malachova, K.;
Jagelska, E. B.; Porubiakova, O.; Cerven, J.; Pecinka, P., In-Depth Bioinformatic Analyses of
Nidovirales Including Human SARS-CoV-2, SARS-CoV, MERS-CoV Viruses Suggest

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.06.190348; this version posted September 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

Important Roles of Non-canonical Nucleic Acid Structures in Their Lifecycles. Front Microbiol
2020, 11, (1583), 1583.
86.

Sapra, A. K.; Anko, M. L.; Grishina, I.; Lorenz, M.; Pabis, M.; Poser, I.; Rollins, J.; Weiland, E.
M.; Neugebauer, K. M., SR protein family members display diverse activities in the formation
of nascent and mature mRNPs in vivo. Mol Cell 2009, 34, (2), 179-90.

87.

Cazalla, D.; Zhu, J.; Manche, L.; Huber, E.; Krainer, A. R.; Caceres, J. F., Nuclear export and
retention signals in the RS domain of SR proteins. Molecular and cellular biology 2002, 22, (19),
6871-82.

88.

Sanford, J. R.; Gray, N. K.; Beckmann, K.; Caceres, J. F., A novel role for shuttling SR proteins
in mRNA translation. Genes Dev 2004, 18, (7), 755-68.

89.

Michlewski, G.; Sanford, J. R.; Caceres, J. F., The splicing factor SF2/ASF regulates translation
initiation by enhancing phosphorylation of 4E-BP1. Mol Cell 2008, 30, (2), 179-89.

90.

Botti, V.; McNicoll, F.; Steiner, M. C.; Richter, F. M.; Solovyeva, A.; Wegener, M.; Schwich, O.
D.; Poser, I.; Zarnack, K.; Wittig, I.; Neugebauer, K. M.; Muller-McNicoll, M., Cellular
differentiation state modulates the mRNA export activity of SR proteins. J Cell Biol 2017, 216,
(7), 1993-2009.

91.

Caceres, J. F.; Screaton, G. R.; Krainer, A. R., A specific subset of SR proteins shuttles
continuously between the nucleus and the cytoplasm. Genes Dev 1998, 12, (1), 55-66.

92.

Dickson, A. M.; Wilusz, J., Strategies for viral RNA stability: live long and prosper. Trends
Genet 2011, 27, (7), 286-93.

93.

Bruscella, P.; Bottini, S.; Baudesson, C.; Pawlotsky, J. M.; Feray, C.; Trabucchi, M., Viruses
and miRNAs: More Friends than Foes. Front Microbiol 2017, 8, 824.

94.

Roberts, A. P.; Lewis, A. P.; Jopling, C. L., The role of microRNAs in viral infection. Prog Mol
Biol Transl Sci 2011, 102, 101-39.

95.

Sacar Demirci, M. D.; Adan, A., Computational analysis of microRNA-mediated interactions
in SARS-CoV-2 infection. PeerJ 2020, 8, e9369.

96.

Khan, M. A.; Sany, M. R. U.; Islam, M. S.; Islam, A., Epigenetic Regulator miRNA Pattern
Differences Among SARS-CoV, SARS-CoV-2, and SARS-CoV-2 World-Wide Isolates
Delineated the Mystery Behind the Epic Pathogenicity and Distinct Clinical Characteristics
of Pandemic COVID-19. Front Genet 2020, 11, 765.

97.

Xu, X.; Chen, P.; Wang, J.; Feng, J.; Zhou, H.; Li, X.; Zhong, W.; Hao, P., Evolution of the novel
coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of
human transmission. Sci China Life Sci 2020, 63, (3), 457-460.

98.

Graham, R. L.; Sparks, J. S.; Eckerle, L. D.; Sims, A. C.; Denison, M. R., SARS coronavirus
replicase proteins in pathogenesis. Virus Res 2008, 133, (1), 88-100.

99.

Srivastava, R.; Budak, G.; Dash, S.; Lachke, S. A.; Janga, S. C., Transcriptome analysis of
developing lens reveals abundance of novel transcripts and extensive splicing alterations. Sci
Rep 2017, 7, (1), 11572.

100.

Budak, G.; Dash, S.; Srivastava, R.; Lachke, S. A.; Janga, S. C., Express: A database of
transcriptome profiles encompassing known and novel transcripts across multiple
development stages in eye tissues. Experimental eye research 2018, 168, 57-68.

101.

Kim, D.; Langmead, B.; Salzberg, S. L., HISAT: a fast spliced aligner with low memory
requirements. Nat Methods 2015, 12, (4), 357-60.

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.06.190348; this version posted September 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

102.

Li, H.; Handsaker, B.; Wysoker, A.; Fennell, T.; Ruan, J.; Homer, N.; Marth, G.; Abecasis, G.;
Durbin, R.; Genome Project Data Processing, S., The Sequence Alignment/Map format and
SAMtools. Bioinformatics 2009, 25, (16), 2078-9.

103.

Wheeler, D. L.; Barrett, T.; Benson, D. A.; Bryant, S. H.; Canese, K.; Chetvernin, V.; Church,
D. M.; Dicuccio, M.; Edgar, R.; Federhen, S.; Feolo, M.; Geer, L. Y.; Helmberg, W.; Kapustin,
Y.; Khovayko, O.; Landsman, D.; Lipman, D. J.; Madden, T. L.; Maglott, D. R.; Miller, V.;
Ostell, J.; Pruitt, K. D.; Schuler, G. D.; Shumway, M.; Sequeira, E.; Sherry, S. T.; Sirotkin, K.;
Souvorov, A.; Starchenko, G.; Tatusov, R. L.; Tatusova, T. A.; Wagner, L.; Yaschenko, E.,
Database resources of the National Center for Biotechnology Information. Nucleic Acids Res
2008, 36, (Database issue), D13-21.

104.

Pertea, M.; Pertea, G. M.; Antonescu, C. M.; Chang, T. C.; Mendell, J. T.; Salzberg, S. L.,
StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nat
Biotechnol 2015, 33, (3), 290-5.

105.

Love, M. I.; Huber, W.; Anders, S., Moderated estimation of fold change and dispersion for
RNA-seq data with DESeq2. Genome biology 2014, 15, (12), 550.

106.

Smoot, M. E.; Ono, K.; Ruscheinski, J.; Wang, P. L.; Ideker, T., Cytoscape 2.8: new features for
data integration and network visualization. Bioinformatics 2011, 27, (3), 431-2.

107.

Cunningham, F.; Amode, M. R.; Barrell, D.; Beal, K.; Billis, K.; Brent, S.; Carvalho-Silva, D.;
Clapham, P.; Coates, G.; Fitzgerald, S.; Gil, L.; Giron, C. G.; Gordon, L.; Hourlier, T.; Hunt, S.
E.; Janacek, S. H.; Johnson, N.; Juettemann, T.; Kahari, A. K.; Keenan, S.; Martin, F. J.; Maurel,
T.; McLaren, W.; Murphy, D. N.; Nag, R.; Overduin, B.; Parker, A.; Patricio, M.; Perry, E.;
Pignatelli, M.; Riat, H. S.; Sheppard, D.; Taylor, K.; Thormann, A.; Vullo, A.; Wilder, S. P.;
Zadissa, A.; Aken, B. L.; Birney, E.; Harrow, J.; Kinsella, R.; Muffato, M.; Ruffier, M.; Searle,
S. M.; Spudich, G.; Trevanion, S. J.; Yates, A.; Zerbino, D. R.; Flicek, P., Ensembl 2015. Nucleic
Acids Res 2015, 43, (Database issue), D662-9.

108.

Bailey, T. L.; Johnson, J.; Grant, C. E.; Noble, W. S., The MEME Suite. Nucleic Acids Res 2015,
43, (W1), W39-49.

109.

de Rie, D.; Abugessaisa, I.; Alam, T.; Arner, E.; Arner, P.; Ashoor, H.; Astrom, G.; Babina, M.;
Bertin, N.; Burroughs, A. M.; Carlisle, A. J.; Daub, C. O.; Detmar, M.; Deviatiiarov, R.; Fort,
A.; Gebhard, C.; Goldowitz, D.; Guhl, S.; Ha, T. J.; Harshbarger, J.; Hasegawa, A.; Hashimoto,
K.; Herlyn, M.; Heutink, P.; Hitchens, K. J.; Hon, C. C.; Huang, E.; Ishizu, Y.; Kai, C.;
Kasukawa, T.; Klinken, P.; Lassmann, T.; Lecellier, C. H.; Lee, W.; Lizio, M.; Makeev, V.;
Mathelier, A.; Medvedeva, Y. A.; Mejhert, N.; Mungall, C. J.; Noma, S.; Ohshima, M.; OkadaHatakeyama, M.; Persson, H.; Rizzu, P.; Roudnicky, F.; Saetrom, P.; Sato, H.; Severin, J.; Shin,
J. W.; Swoboda, R. K.; Tarui, H.; Toyoda, H.; Vitting-Seerup, K.; Winteringham, L.;
Yamaguchi, Y.; Yasuzawa, K.; Yoneda, M.; Yumoto, N.; Zabierowski, S.; Zhang, P. G.; Wells,
C. A.; Summers, K. M.; Kawaji, H.; Sandelin, A.; Rehli, M.; Consortium, F.; Hayashizaki, Y.;
Carninci, P.; Forrest, A. R. R.; de Hoon, M. J. L., An integrated expression atlas of miRNAs
and their promoters in human and mouse. Nat Biotechnol 2017, 35, (9), 872-878.

110.

Fan, Y.; Siklenka, K.; Arora, S. K.; Ribeiro, P.; Kimmins, S.; Xia, J., miRNet - dissecting
miRNA-target interactions and functional associations through network-based visual
analysis. Nucleic Acids Res 2016, 44, (W1), W135-41.

111.

Fan, Y.; Xia, J., miRNet-Functional Analysis and Visual Exploration of miRNA-Target
Interactions in a Network Context. Methods Mol Biol 2018, 1819, 215-233.

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.06.190348; this version posted September 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

nsp2
nsp5
nsp5_C145A

nsp8

nsp9
nsp11

nsp12

nsp13
E
M
orf7a
orf9b

N

Retina
Frontal Cortex
Spinal Cord
Platelets
Adrenal
Ovary
Testis
Pancreas
Placenta
B Cells
CD4 Cells
Heart
Esophagus
Lung
Kidney
Liver
Gallbladder
Rectum
Colon
Prostate
Monocytes
Urinary Bladder
CD8 Cells
NK Cells

SARS-CoV-2
proteins

Fetal Heart
Fetal Liver
Fetal Gut
Fetal Testis
Fetal Ovary
Fetal Brain

row max
row min

B

Protein Abundance

A

RBPs

EIF4E2
GIGYF2
HDAC2
TRMT1
AATF
CCDC86
DDX10
EXOSC2
LARP7
MEPCE
MPHOSPH10
MRPS27
MRPS5
NGDN
NOL10
SRP19
SRP54
SRP72
EIF4H
TBCA
AKAP8
LARP4B
PRRC2B
RBM41
UBAP2
UBAP2L
ZC3H7A
GOLGB1
RDX
ZC3H18
AKAP8L
BZW2
FASTKD5
RTN4
MDN1
CSDE1
MARK2
PTBP2
DDX21
FAM98A
G3BP1
G3BP2
LARP1
MOV10
PABPC1
PABPC4
RBM28
RPL36
RRP9
SNIP1
UPF1

A

wound healing, spreading of epidermal cells
regulation of lipid metabolic process
regulation of p38MAPK cascade
positive regulation of protein kinase A signaling
Transcriptional misregulation in cancer
response to hypoxia
cornification
positive regulation of cell adhesion
regulation of lipid storage
regulation of smooth muscle cell proliferation
regulation of body fluid levels
regulation of inflammatory response
positive regulation of protein phosphorylation
receptor ligand activity
Measles
Signaling by Interleukins
Interleukin-10 signaling
Interleukin-1 signaling
inflammatory response
response to lipopolysaccharide
response to external biotic stimulus
Immune System
response to other organism
cytokine-mediated signaling pathway
IL-17 signaling pathway

#DEGs (at 5% fdr)

142

4

B

Mock treated

20

NHBE cells
rep3

SARS-CoV-2 infected

rep1

rep2

row max

rep2

10

- log10 p-adj.value

row min

Expression (in CPM)

rep1

0

(Differentially expressed at 5% fdr)

rep3

RBPs
ZNFX1
SAMD4B
FLNB
HDGF
ASS1
ZC3H12A
HK2
BST2
PARP12
PPARGC1A

400

Alternatively spliced
events (at 5% fdr)

350
300
250
200

31

150

13

100

6

50
0

B

36

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.06.190348; this version posted September 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

Alternatively spliced genes

A

SE

MXE

A3SS

A5SS

5

RI

A
0.0

0.2

0.4

0.6

B

0.8

1.0
SFPQ
CSTF2
CELF1
ELAVL2
HNRNPU
YBX1
SRSF3
TRA2A
FMR1
PABPC1
SRSF7
SYNCRIP
SNRPA
PUM2
HNRNPA1
SRSF10
PCBP2
TARDBP
PCBP1
ELAVL4
ELAVL1
PUM1
PTBP1
SRSF2
SF1
SRSF1

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.06.190348; this version posted September 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

Frequency

Open reading frames
1a

Structural proteins
1b

S

Non-structural proteins [nsp]
1

2

3

4

5

6

8

12

Spinal Cord
Heart
Esophagus
Platelets
Frontal Cortex
Urinary Bladder
Lung
Liver
Gallbladder
Colon
Prostate
Kidney
Rectum
Monocytes
Ovary
Testis
Pancreas
B Cells
Retina
CD8 Cells
Adrenal
Placenta
CD4 Cells
NK Cells

SARS-CoV2 genome
(Normalized Length)

13

14

15 16

Accessory
3a
factors
[n=9]
3b

E

N

M

6 8 9c
7a 9b 10
7b

Protein Abundance
row min

row max

SFPQ
CSTF2
CELF1
ELAVL2
HNRNPU
YBX1
SRSF3
TRA2A
FMR1
PABPC1
SRSF7
SYNCRIP
SNRPA
PUM2
HNRNPA1
SRSF10
PCBP2
TARDBP
PCBP1
ELAVL4
ELAVL1
PUM1
PTBP1
SRSF2
SF1
SRSF1

B

SARS-CoV-2 genome
(Normalized Length)
0.2

0.0

0.4

0.6

Hepatocytes
CD8 cells
NK cells
Blood
Prostate
Epithelial cells
CD19 cells
CD4 cells
Fibroblast
Skeletal muscle cells
Pancreas
Smooth Muscle Cells
Colon
Macrophages
Bone marrow
Endothelial Cells
Skin
Esophagus
Spinal cord
Pituitary gland
Pineal gland
Lymphatic Endothelial cells
CD3 cells
Epithelial cells
Renal
Trachea
Lipocytes
Lung
Brain
Dendritic cells
CD14 cells
Breast
Adipocytes
Smooth muscle
Placenta
Neutrophils
Mast cells

A

0.8

1.0
miR-559
miR-3529-3p
miR-451b
miR-499b-3p
miR-548f-5p
miR-548aj-3p
miR-5688
miR-548g-5p
miR-520d-5p
miR-1468-3p
miR-548aj-5p
miR-548j-3p
miR-548x-5p
miR-499a-3p
miR-29a-3p
miR-21-3p
miR-374a-3p
miR-194-5p

miR-29a-3p
miR-8054
miR-520d-5p
miR-3529-3p
miR-451b
miR-548f-5p
miR-548j-3p
miR-374a-3p
miR-559
miR-548g-5p
miR-548x-5p
miR-548aj-5p
miR-548aj-3p
miR-5688
miR-21-3p
miR-2054
miR-5197-3p
miR-3591-3p
miR-499a-3p
miR-194-5p
miR-1468-3p
miR-499b-3p

bioRxiv preprint doi: https://doi.org/10.1101/2020.07.06.190348; this version posted September 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in
perpetuity. It is made available under aCC-BY-ND 4.0 International license.

Log10 expression (CPM)

Open reading frames
1a

Structural proteins
1b

S

Non-structural proteins [nsp]
1

2

3

4

5

6

8

12

13

14

15 16

Accessory
3a
factors
[n=9]
3b

E

N

M

6 8 9c
7a 9b 10
7b

-log10 p-adj.value

C

row min

30
20
10
0

row max

